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A REVIEW OF THE REAL-WORLD INCIDENCE OF MAJOR BLEEDING 
AFTER ANTICOAGULANT USE IN ATRIAL FIBRILLATION PATIENTS IN 
THE UNITED STATES  
 
PATRICK J. MCBEE 
 
 
ABSTRACT 
 
Objective: To comprehensively review real-world database studies in the United States 
that assess the risk of major bleeding among direct oral anticoagulant (DOAC) therapies 
or warfarin in a nonvalvular atrial fibrillation (NVAF) population.  
Background: NVAF patients receiving anticoagulant therapy to reduce the risk of stroke 
or blood clots are at a higher risk of serious bleeding complications with the use of 
warfarin or other anticoagulant agents.  
Methods: Reviewed MEDLINE (via Pubmed) and bibliographies of identified literature 
for publications and conference abstracts of retrospective observational studies using U.S. 
data sources from the first available date to June 15th, 2018.  
Results: A total of 26 real-world database studies were identified and fully reviewed. 
Most studies utilized data from administrative claims or forms of patient registries (n = 
25). Patient populations assessed were generally older and male. Apixaban resulted in 
statistically significant reductions in bleeding risk compared to warfarin in most studies 
that assessed the relationship (n = 11). Dabigatran was less consistently shown to exhibit 
		 vi 
a lower bleeding risk compared to warfarin; nine studies reported lower risk, though only 
three studies were statistically significant. In a head-to-head comparison, however, 
apixaban and dabigatran generally showed no significant difference. Bleeding risk for 
rivaroxaban was similar to warfarin. No studies were found that evaluated the bleeding 
risk of edoxaban.  
Conclusions: Overall, DOACs exhibit a lower risk of major bleeding compared to 
warfarin, although with significantly different rates. Apixaban most consistently shows 
reduced risk of bleeding in the real-world compared to warfarin, followed by dabigatran. 
More evidence is needed to evaluate the recently approved agent edoxaban.    
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INTRODUCTION 
Atrial Fibrillation 
Atrial fibrillation (AF) is a common heart arrhythmia which affects approximately 
33 million people worldwide and at least 6 million individuals in the United States.1–3 
150,000 new cases of AF are diagnosed each year and 95% are classified as nonvalvular 
atrial fibrillation (NVAF).4,5 The distinction between NVAF and other forms of the 
condition is made when the patient shows no signs of rheumatic mitral valve disease and 
has not undergone surgery for placement of a prosthetic heart valve or mitral valve 
repair.6 On an electrocardiogram, AF is characterized by an absence of coordinated 
depolarization of the atria (e.g. absent P-waves) as well as unpredictable depolarization of 
ventricles (e.g., irregular R waves), as shown in Figure 1.7  It is estimated that the 
incidence of NVAF ranges between 1.9 and 9.9 per 1000 person-years8 and with an 
increasing proportion of the population becoming elderly, the prevalence of AF is 
estimated to grow to 12.1 million by 2030.9  
Patients suffering from NVAF exhibit a 5-fold increased risk of stroke and 
doubled all-cause mortality rates.10 Approximately 20% of strokes due to AF are fatal and 
60% will result in serious disability.11 Additionally, approximately 15% of all ischemic 
strokes and 30% of strokes in patients over 80 years of age are due to NVAF.12 Identified 
risk factors for AF include age, male gender, hypertension, diabetes, thyroid disease, 
congestive heart failure, sleep apnea, and renal failure.10,13 
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Figure 1. Atrial Fibrillation Electrocardiogram Review. Classic characteristics 
of EKGs of patients exhibiting Atrial Fibrillation include an irregular rhythm, the absence 
of P waves, the absence of an isoelectric baseline, variable ventricular rate, and QRS 
complexes usually < 120 ms. Figure taken from CardioNetworks.7 
 
Anticoagulant Treatment for NVAF 
Oral anticoagulant therapy with warfarin is recommended for the prevention of 
stroke in patients with AF.10,14 Previously, warfarin, classified as a vitamin-K 
anticoagulant, was the only effective anticoagulant treatment available to NVAF patients 
and it has been widely used for the past 50 years.15,16 However, warfarin is associated 
with a number of limitations, including a slow onset of action, narrow therapeutic margin, 
inadequate anticoagulation, high discontinuation rate, frequent and complex dose 
adjustments, increased risk of bleeding, variability in dose response, drug and food 
interactions, and lack of standardization in coagulation monitoring in the laboratory.17 
Typically, a normal adult dose of warfarin is 2 – 5 mg/d for 2 – 4 days, followed by 1 – 
10 mg/d, as indicated by international normalized ratios (INR) values.18 
Routine testing of INR values must be undertaken for patients receiving 
warfarin.18 The INR is calculated from the patient’s prothrombin time and is used to 
measure the degree of anticoagulation and level of compliance. Ranges of INR values 
have been identified which maximize the reduction in stroke and venous 
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thromboembolism (VTE) risk while minimizing the risk of bleeding. For most patients 
and indications, the target INR value is between 2 – 3; values outside of this range are 
indicative of either ineffective treatment (below 2) or significantly increased risk of 
bleeding (above 3).18 Therefore, routine INR testing represents a notable limitation for 
patients receiving warfarin therapy due to the regularity in which tests must be 
completed. This major limitation has resulted in poor patient adherence and most likely 
contributes to underuse of warfarin and vitamin K antagonists for stroke prevention.19,20  
In the past decade, nonvitamin-K anticoagulants, also referred to as direct oral 
anticoagulants (DOACs), have emerged as alternative therapeutics for patients with 
NVAF that exhibit considerable advantages over treatment with warfarin. The new oral 
anticoagulants have predictable anticoagulant effects that enable the administration of 
fixed doses without requiring periodic coagulation monitoring, which greatly simplifies 
treatment.21 To date, four DOACs are approved by the Food and Drug Administration 
(FDA) for the prevention of stroke or recurrent VTE: dabigatran, rivaroxaban, apixaban, 
and edoxaban. Dabigatran competitively and reversibly blocks thrombin, an enzyme in 
plasma that causes the clotting of blood, while rivaroxaban, apixaban, and edoxaban act 
by inhibiting clotting factor Xa (FXa), as shown in Figure 2. DOAC agents act in more 
targeted and precise locations along the coagulation cascade compared to warfarin, which 
acts on numerous blood factors.
	 
 
Figure 2. Classical Blood Coagulation Pathway. The process of forming a blood clot involves a coagulation cascade in 
which the final product, fibrin, is utilized to stop blood flow. Intrinsic and extrinsic pathways activate blood factor 
zymogens which catalyze downstream reactions. Anticoagulants such as warfarin, apixaban, rivaroxaban, edoxaban and 
dabigatran act to prevent clot formation by inhibiting various clotting factors in each pathway. Source: Self-produced.  
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Clinical Trials of Direct Oral Anticoagulants 
Clinical trials of DOACs demonstrated significant advantages of the new 
anticoagulants compared to warfarin, including a more rapid anticoagulant effect, similar 
or superior effectiveness, and decreased safety complications such as major bleeding.22–25 
The four phase 3 clinical trials included the following studies: Randomized Evaluation of 
Long Term Anticoagulation Therapy (RE-LY; dabigatran), Rivaroxaban Once Daily Oral 
Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF; rivaroxaban), Apixaban 
for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE; apixaban), and the ENGAGE AF–TIMI 48 study (edoxaban). Table 1 
describes the sample size of the four major clinical trials that evaluate each FDA 
approved DOAC compared to warfarin.  
 
Table 1. Sample Size of Direct Oral Anticoagulant Clinical Trials. Four major 
clinical trials have been conducted to illustrate the effectiveness and safety of new oral 
anticoagulants compared to warfarin. 
Direct Oral 
Anticoagulant 
Trial Name Sample Size 
Dabigatran RE-LY23 D: 150 mg (n=6076) 
D: 110 mg (n=6015) 
W: (n=6022) 
Rivaroxaban ROCKET-AF25 R: (n=7131) 
W: (n=7133) 
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Apixaban ARISTOTLE22 A: (n=9120) 
W: (n=9081) 
Edoxaban ENGAGE AF-TIMI24 E: 60 mg (n=7035) 
E: 30 mg (n=7034) 
W: (n=7036) 
Abbreviations: A, apixaban; D, dabigatran; E, edoxaban; R, rivaroxaban; W, warfarin.  
 
  
Despite the potential advantages of DOAC therapy compared to warfarin, there 
exist significant pharmacodynamics and pharmacokinetic differences between DOACs 
which may influence clinical use.17  
Complications with Anticoagulant Use: Major Bleeding 
Physicians must consider the safety profile of anticoagulant therapy when treating 
patients with NVAF. All antithrombotic therapeutics increase the risk of bleeding. 
Bleeding risk is increased with the duration and dosage of anticoagulant therapy, the use 
of other hemostasis interfering medications, and the presence of any anatomical 
bleeding.18 Major bleeding is most often defined as intracranial bleeding, gastrointestinal 
bleeding, or bleeding from other sites as identified through specific ICD-9-CM 
(International Classification of Diseases, Ninth Revision, Clinical Modification) 
diagnosis codes, although there is no exact consensus from researchers.26  One commonly 
used method for identifying major bleeding in retrospective database studies includes 
using the criteria from Yao et al, Table 2.  
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Table 2. Diagnosis Codes for Identifying Major Bleeding Among Atrial Fibrillation 
Patients on Oral Anticoagulants. Retrospective database studies commonly identify 
major bleeding episodes based off of intracranial, gastrointestinal or other bleeding sites. 
Source: Table adapted from Yao et al 2016.  
 
 Data from clinical trials have shown that the incidence of major bleeding among 
patients receiving dabigatran 150 mg and rivaroxaban 20 mg was not significantly 
different from warfarin.23,25  However, dabigatran 110 mg, apixaban 2.5 mg and 5 mg, as 
well as edoxaban 30 mg and 60 mg resulted in a lower risk of major bleeding compared 
to warfarin.22–24 No clinical trials to date have made direct comparisons of major bleeding 
across DOAC agents, although indirect comparisons confirmed that bleeding incidence 
varies by DOAC treatment.27,28 For example, apixaban 5 mg and edoxaban 30 mg have 
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been shown to significantly reduce the risk of major bleeding compared to rivaroxaban 
20 mg as well as dabigatran 150 mg (standard dose). Similarly, a high dose of edoxaban 
(60 mg) was associated with significant reduction in the risk of major bleeding compared 
to rivaroxaban 20 mg, but not standard-dose dabigatran. There have been no significant 
differences reported between edoxaban 60 mg, apixaban 5 mg, and dabigatran 110 
mg.27,29–31  
Bleeding in NVAF patients from anticoagulant use may lead to serious and 
potentially fatal outcomes and result in larger medical resource utilization and costs.32 
For example, one study found that 3.3% of AF patients underwent major bleeding after 
being treated with a FXa inhibitor.33 For those patients with major bleeding, the mean 
hospital length of stay was 5.3 days and the average hospital cost was $28,059. The total 
all-cause costs were also significantly higher in the 12 months following the event for 
patients exhibiting a major bleeding episode compared to those without ($63,866 vs 
$37,916, p < 0.001). In total, it is estimated in the U.S. that managing NVAF costs $6.65 
billion on an annual basis, including an overall cost of $4.88 billion in hospitalization 
expenses and $1.53 billion in outpatient costs.34 However, there are estimates that the use 
of DOACs can reduce the cost of NVAF by preventing strokes. One study concluded that 
the use of apixaban and dabigatran result in total medical cost reductions of $1245 and 
$555 per patient year, respectively, compared to warfarin. The same researchers found 
that rivaroxaban resulted in a medical cost increase of $144.35  
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Clinical Trials vs Real-World Data 
Randomized controlled trials (RCTs) are the gold standard for assessing the 
effectiveness of a treatment on a diseased population and represent the highest level of 
evidence due to the minimization of confounding factors and elimination of major 
differences between study groups.36,37 However, the populations and settings used in 
controlled clinical trials lack representativeness of the overall population and thus are not 
always generalizable to what is observed in clinical practice.38 Therefore, the high level 
of internal validity comes at the expense of uncertain generalizability due to clinical trial 
populations that do not mirror those seen in everyday clinical practice.38 Furthermore, the 
cost of conducting clinical trials is often very high and the duration to complete such 
studies is long.39  
Recently, retrospective analyses utilizing administrative insurance claims, 
electronic medical records (EMR), hospital (chargemaster) data, or registry data have 
aimed to complement the findings of clinical trials by providing a comparison of what is 
observed in the “real-world”, or clinical setting. EMR, registry, administrative claims, 
and hospital databases contain rich data collected at the point of care in office or from 
medical devices or applications that continuously monitor an endpoint. The level of 
accuracy from these sources is undetermined however, because real-world data sources 
are not primarily designed for research purposes.40,41 Nevertheless, conclusions from real-
world data sources have begun to influence healthcare decision making at high levels. For 
example, the FDA has started to use real-world data to monitor the safety and 
effectiveness of medical devices.41,42  
	 10	
Unlike RCTs, however, numerous levels of confounding variables may exist in 
retrospective studies due to the aggregation of data sources as well as heterogeneous 
populations. The exclusion of appropriate statistical measures to limit confounding 
factors, such as propensity score matching, among other statistical techniques, may lead 
to errors in decision making from inaccurate inferences among real-world studies. 
Therefore, retrospective observational studies may fail to consistently complement the 
findings of the more statistically robust RCT.  
Recognizing the importance of the bleeding complications due to DOAC use, 
industry pharmaceutical manufacturers including Pfizer (apixaban), Daiichi Sankyo 
(edoxaban), Boehringer Ingelheim (dabigatran), as well as Janssen Pharmaceuticals and 
Bayer AG (rivaroxaban) continue to fund real-world studies aimed at demonstrating 
superiority between agents. In 2016, Deitelzweig and colleagues published a review of 26 
observational studies evaluating major bleeding rates among DOACs in NVAF 
populations worldwide.43 The review was sponsored by Pfizer, and reported that 
apixaban consistently showed lower bleeding rates compared to alternative DOACs. 
However, numerous other studies assessing the same outcome in the real-world have 
since been published. Therefore, an updated, independent review of the published 
literature examining which anticoagulant, if any, leads to the fewest major bleeding 
complications among NVAF patients is warranted and may impact prescribing patterns 
from physicians of anticoagulants. 
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Objectives and Rationale 
The primary objective of the present analysis is to provide a comprehensive 
review of available real-world observational studies analyzing the risk of major bleeding 
after use of dabigatran, rivaroxaban, apixaban, or edoxaban in an NVAF population in the 
United States. A secondary objective is to examine the methodology used between 
studies and explore possible explanations for any statistical discrepancies that 
significantly alter the identified risk of major bleeding. These reasons may include, but 
are not limited to, differences between study populations and datasets, study time periods, 
or statistical methods used to minimize confounding. Understanding the differences 
between the performance of DOACs in clinics and hospitals versus controlled clinical 
studies will provide valuable insight to clinicians and researchers who aim to better 
control complications among NVAF patients and improve patient outcomes.  
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PUBLISHED STUDIES 
Search Strategy for Literature Review 
  A literature search was performed in MEDLINE (via Pubmed) to identify 
observational studies for the period of first available date to June 15, 2018. Due to a lack 
of defined MeSH terms related to real-world analyses, a manual search was performed 
with the following terms: (apixaban OR edoxaban OR dabigatran OR rivaroxaban OR 
NOAC OR DOAC) AND (real world OR observational OR registry OR claims OR EMR 
OR EHR) AND (complication OR safety OR bleeding) AND (NVAF OR nonvalvular 
atrial fibrillation OR AF). The search yielded 324 preliminary results, of which the titles 
and abstracts were reviewed to determine on-target publications.  
Citations that met eligibility criteria underwent full screening and review. Only 
studies that utilized data sources from the United States were included in the review. 
Studies utilizing ex-US sources were excluded because of the inherent differences 
between international healthcare systems (i.e. single payer vs commercial) and to ensure 
relative consistency in treatment patterns and care guidelines.  Ideally, by considering 
only US studies, one can make a more direct comparison across real-world studies. 
 Similarly, studies which did not report hazard ratios assessing the risk of major 
bleeding between DOAC agents or warfarin were not considered for this review. 
Bibliographies of fully reviewed papers were also cross-checked for other relevant 
studies. Review articles were also utilized to identify other studies not otherwise captured 
in the above algorithm. Relevant abstracts identified through reviews and other 
publications were also included. Similarly, manual searches of scientific meetings 
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including the American College of Cardiology, European Stroke Conference, and the 
American Heart Association were thoroughly reviewed for additional sources and 
completeness. 
 For cases in which an original publication had been published and later updated 
with similar results, only the latter published article was fully reviewed. For example, 
Abraham and colleagues initially utilized the Optumlabs Data Warehouse to examine the 
risk of gastrointestinal bleeding with the use of DOACs in 2015, and subsequently 
published an updated study using the same data source and methods in 2017. Only the 
2017 paper is included in this review.  
 Of note, unlike many published systematic reviews, this analysis does not 
consider the quality of the publication or abstract reviewed; therefore, all on-target 
publications that were identified were also included. Additionally, data extraction was 
completed solely by the author and was not cross-referenced by any other individual. In 
rare cases in which the publication or abstract did not provide overall numerical values 
for a given variable (for example, the mean age), values were best approximated with the 
information provided, see Tables 3 and 4.  
Overview of Study Characteristics 
 
Overall, 26 studies were fully reviewed (20 peer-reviewed publications and 6 
conference abstracts). Table 3 provides a summary of the included studies. All studies 
were conducted using U.S. data sources and all were categorized as retrospective cohort 
studies (as compared to prospective). Most studies exhibited large sample sizes of 
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patients, used propensity score matching to address possible confounding, and included 
patients with only new onset AF who initiated standard dose DOACs to minimize 
variability in exposure definition. The majority of studies were industry funded (n =14) 
while the remaining were independent and did not report significant conflicts of interest 
(n= 12). Due to edoxaban’s more recent approval compared to dabigatran, apixaban and 
rivaroxaban, there were no studies that included edoxaban in analysis of major bleeding 
risk; however, all other approved anticoagulants were present throughout multiple 
studies.  
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Table 3. Study Characteristics.  
All studies utilized data sources from the United States and compared direct oral anticoagulants or warfarin. Data 
shown were compiled directly from primary sources or other published literature reviews. See below for legend and 
abbreviations.  
First Author, 
Year 
Abstract or 
Publication 
Study 
Design 
Industry vs 
Independent 
Country and 
Data Source 
Study 
Period 
Sample 
Size 
Interventions 
Evaluated 
Abraham, 
201744 
Publication R Independent  OptumLabs 
Data 
Warehouse 
Oct. 2010 –  
Feb. 2015 
 31,574  A vs D  
A vs R  
R vs D  
Adeboyeje, 
201645 
Abstract R Independent HealthCore 
Integrated 
Research 
Environment 
Nov. 2010 – 
Feb. 2015 
 44,057  A vs. W 
D vs. W 
Riva vs. W 
A vs. D 
A vs. Riva 
D vs. Riva 
Amin, 201546 Abstract R Industry 
(Pfizer) 
Optum 
Research 
Database 
Jan. 2013 – 
Dec. 2014 
 36,260  A vs. W 
A vs. Riva 
A vs. D 
Bengtson, 
201747 
Publication R Independent MarketScan Jan. 2009 –  
Dec. 2012 
 61,648  D vs W  
Coleman, 
2017*48 
Publication R Industry 
(Bayer) 
MarketScan Jan. 2012 –  
June 2015 
 9,684  A vs W  
D vs W  
R vs W  
Coleman, 
201649 
Publication R Industry 
(Bayer) 
MarketScan Jan. 2012 –  
Oct. 2014 
 30,988  A vs W 
R vs W 
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Deitelzweig, 
201750 
Publication R Industry 
(Pfizer) 
Medicare 
Advantage 
from Humana 
database 
Jan. 2013 –  
Sept. 2015 
 19,332  A vs R  
A vs D 
A vs W  
Deitelzweig, 
201551 
Abstract R Industry 
(Pfizer) 
PharMetrics 
Plus data 
Jan. 2012 – 
Sept. 2014 
 24,573  A vs. W 
A vs. D 
A vs. Riva 
Graham, 
201552 
Publication R Independent Medicare –  
134,41
4  
D vs. W 
Graham, 
201653 
Publication R Independent Medicare Nov. 2011 – 
June 2014 
 
118,89
1  
Riva vs. D 
Hernandez, 
201554 
Publication R  Independent Medicare data Oct. 2010 – 
Oct. 2011 
 9,404  D vs W  
Kamble, 
201555 
Abstract R Industry 
(Pfizer) 
MarketScan 
Commercial 
and Medicare 
Supplemental 
US database 
Jan. 2012 – 
Dec. 2013 
 26,604  D vs. W 
A vs. W 
Riva vs. W 
Laliberte, 
201456 
Publication R Industry 
(Janssen) 
Healthcare 
claims from 
Symphony 
Health 
Solutions’ 
Patient 
Transactional 
Datasets 
May 2011 – 
Jul. 2012 
 18,270  Riva vs. W 
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Lauffenburger
, 201557 
Publication R Independent Truven Health 
MarketScan 
Commercial 
Claims and 
Encounters 
and Medicare 
supplement 
databases 
Oct. 2010 –  
Dec. 2012 
 64,935  D vs W  
Li, 201858 Publication R Industry 
(Pfizer) 
Pooled of 4: 
US 
MarketScan, 
Pharmetrics, 
Optum, and 
Humana 
Jan. 2012 –  
Sept. 2015 
 
115,18
6  
2.5 mg A vs 
W 
5 mg A vs W 
Lin, 201559 Abstract R Industry 
(Pfizer) 
Humedica de-
identified 
Electronic 
Health Record 
data 
Jan. 2013 – 
Jun. 2014 
 35,757  A vs. W 
A vs. D 
A vs. Riva 
Lip, 201660 Publication R Industry 
(Pfizer) 
Truven 
MarketScan 
Commercial 
Claims and 
Encounter and 
Medicare 
Supplemental 
and 
Coordination 
of Benefits 
Databases 
Jan. 2013 –  
Dec. 2013 
 29,338  A vs W  
D vs W  
R vs W  
	 
18		
Lip, 2016*61 Publication R Industry 
(Pfizer) 
Truven 
MarketScan 
Commercial 
Claims and 
Encounter and 
Medicare 
Supplemental 
and 
Coordination 
of Benefits 
Databases 
Jan. 2012 – 
Dec. 2014 
 9,030  D vs. W 
Martinez, 
201862 
Publication R Independent MarketScan Nov. 2011 –  
Dec. 2016 
 21,508  A vs W  
D vs W  
R vs W  
Norby, 201763 Publication R Independent MarketScan Jan. 2010 – 
Dec. 2014  
 
111,90
5  
R vs D  
R vs W  
Noseworthy, 
2016*64 
Publication R Independent Optum Labs 
Data 
Warehouse 
Oct. 2010 – 
Feb. 2015 
 13,084  A vs. D 
Palamaner 
Subash 
Shantha, 
201765 
Publication R Independent Medicare data Nov. 2011 – 
Oct. 2013 
 
146,87
1  
R vs W 
D vs W 
R vs D 
Seeger, 201566 Publication R Industry 
(Boehringer 
Ingelheim) 
MarketScan, 
Truven and 
Clinformatics, 
Optum 
Oct. 2010 – 
Dec. 2012 
 38,378  D vs. W 
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Tepper, 
201567 
Abstract R Industry 
(Pfizer) 
MarketScan 
Earlyview 
insurance 
claims 
database 
Jan. 2013 – 
Oct. 2014 
 60,277  A vs. D 
A vs. Riva 
Villines, 
201568 
Publication R Industry 
(Boehringer 
Ingelheim) 
DoD 
healthcare 
database 
Oct. 2009 – 
Jul. 2013 
 25,586  D vs. W 
Yao, 2016*26 Publication R Independent OptumLabs 
Data 
Warehouse 
Oct. 2009 – 
Jul. 2015 
2013 
 28,614  D vs. W 
 Abbreviations. A, apixaban; D, dabigatran; NR, not reported; Riva, Rivaroxaban; N, No; R; retrospective; SD, 
standard deviation; W, Warfarin; Y, Yes. 
*No total sample provided; numbers represent sample size within each propensity-score matched comparison. 
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Data Sources 
The data sources utilized included administrative claims or patient registries (n = 
25) and EMR (n = 1). Two publications utilizing EMR data were initially identified, 
although one study did not include hazard ratios characterizing the risk of major bleeding 
using DOACs or warfarin and was therefore excluded.69  
The most common data source used was the Truven MarketScan database (n = 
13). The database, owned and operated by Truven Health Analytics (Ann Arbor, MI, 
USA), is composed of administrative healthcare claims for employees of large self-
insured companies as well as members of private plans in the US. Claims contain a 
unique patient identifier which is encrypted and is used to construct a longitudinal record 
of pharmacy and medical services for each individual. To ensure that patients are eligible 
for benefits during the period of study, membership information is supplied. Medical 
information is obtained from the ICD-9-CM diagnosis codes contained in the claims. 
Pharmacy claims provide the dispensed drug using the National Drug Code coding 
system. Each claim contains provider of service, date of service, and information about 
units for physician services or the date that medications were dispensed. The database is 
composed of two different populations. The “commercial” population represents patients 
<65 years of age and not otherwise covered by Medicare (the US government program 
for those ≥65 years of age). The second population consists of “Medicare Supplemental” 
patients who are ≥65 years and participate in the Medicare program or continue to be 
covered by their employer’s health plan.  
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Summary of Population Characteristics 
 Overall, studies assessed patient populations that were older (the range of means 
was 67 – 85 years of age) and primarily male (n = 23). Table 4 provides baseline 
characteristics of patients. A majority of studies assessed patients that were naïve to 
DOAC anticoagulant therapy (n = 21). Additionally, most studies (n = 15) identified AF 
patients by utilizing the ICD-9-CM code 427.31, which has been validated to identify AF 
patients with a median positive predictive value of 89%.70 However, some studies (n = 5) 
included codes 427.3 and 427.32 as well and the remaining studies (n = 6) did not report 
which codes were used to identify AF patients.  
The majority of studies (n = 19) provided information regarding the risk of stroke 
at baseline via the CHADS2 or CHA2DS2Vasc scores. CHADS2 score is a measure used 
to predict the risk of stroke in patients with AF.54 To calculate the CHADS2, a history of 
previous stroke or transient ischemic attack is assigned 2 points; chronic heart failure, 
hypertension, age of 75 years or older, and diabetes mellitus are assigned 1 point each. 
Finally, the resulting CHADS2 score is the sum of all points for any individual patient. 
Similarly, CHA2DS2Vasc score is a validated score to assess a patient’s risk of stroke and 
is used to determine which patients with NVAF are likely to benefit from anticoagulant 
therapy. A score of >1 indicates that anticoagulation therapy should be considered.71 The 
range of mean values for the CHADS2 score between studies was 1.7 – 4.0 while that of 
the CHA2DS2Vasc score was 2.0 – 5.0.  
Ten studies provided the risk of bleeding at baseline by reporting HAS-BLED72 
scores among populations. A HAS-BLED score ranges from 0 (low risk) to 9 (very high 
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risk) based on a patient’s medical history of hypertension, abnormal renal and liver 
function, stroke, bleeding, labile INR, elderly status, and drugs or alcohol. A patient with 
a score ≥3 is considered to be at high risk of major bleeding. Of the studies reviewed, a 
range of HAS-BLED scores from 1.2 – 3.4 was observed, suggesting that study 
populations differed in initial risk of major bleeding.  
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Table 4. Summary of Population Characteristics. Overall population characteristics of each study determine 
the degree of similarity of patients between studies. Studies exhibiting similar populations are more likely to be 
comparable, which allows the effects of oral anticoagulants to be more readily ascertained with respect to major 
bleeding. Overall, most studies examined elderly populations that were primarily male and naïve to DOAC 
treatment.    
First Author, 
Year 
Age, Years, 
Mean (SD) or 
Range (SD)  
Male 
(%) 
CHADS2 
[CHA2DS2Vasc], 
Mean or Range 
(SD or IQR) 
HAS-
BLED, 
Mean (SD 
or IQR) 
DOAC Naïve 
(Y/N/Unclear) 
Diagnostic 
Code 
Abraham, 
2017 
69.2 (11.6) - 
72.2 (11.1)  
59.3 –  2.2 – 2.4  N 427.31 
Adeboyeje, 
2016 
70 (12.3) 59 [3.3 (9)] –  Y 427.31 
Amin, 2015 –  51.9 [4.2] –  Y 427.31 
Bengtson, 
2017 
68.5 (12.3) - 
72.5 (12.2) 
60* 2.5 (1.5 - 1.6) –  Y (naïve vs 
switchers) 
427.3, 
427.31 and 
427.32 
Coleman, 
2017 
73 53* 4 [5]* 3 Y 427.31 
Coleman, 
2016 
70 54* 1.9 (1.1) [3.5 (1.4)] 1.6 (0.7) Y 427.31 
Deitelzweig, 
2017 
77.2 (8.6) - 78.2 
(9.0) 
53* 2.6 (1.3) [4.4 (1.6)] 3 Y 427.31 
Deitelzweig, 
2015 
66.5 71.4 [2.6] 2 Y 427.31 and 
427.32 
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Graham, 2015 –  48.5 –  –  Y ICD-9 (NR) 
Graham, 2016 –  53 –  –  Y ICD-9 (NR) 
Hernandez, 
2015 
75 (10) 42* –  –  Unclear 427.31 
Kamble, 2015 67 (11.9) 67.4 –  –  Y –  
Laliberte, 
2014 
73.5 (8.4) 49 2 (1) [3.4 (1.4)] 1.9 (0.8) Y 427.31 
Lauffenburger, 
2015 
69.9 (12.4) 60.1 [2.3 – 2.9] (1.6 – 
1.7) 
–  Y 427.31 
Li, 2018 68.6 –  82.5 (8.5 
–  11.7) 
50* 2 – 3 (2.3 – 2.7) [3 
– 4.5 (1.5 – 1.7)] 
2.5 – 3.3 
(1.3) 
Y 427.31 
Lin, 2015 –  55.2 –  –  Y 427.31 
Lip, 2016 69* 63* 1.7 – 2.0 (1.2 – 1.3) 
[2.8 – 3.2](1.6) 
–  Y 427.31 and 
472.32 
Lip, 2016 69 (12.3) 61.3 1.8 (1.2) [2.8 (1.7)] 2.2 (1.3) Y 427.31 or 
427.32 
Martinez, 
2018 
85* 63* 4 (4, 5) [2 (2, 3)] 2 (2 – 3) Y 427.31 
(ICD10 = 
I48) 
Norby, 2017 70* 62* [2.6 – 4.0 (1.9 – 
2.1)] 
–  Y  427.3, 
427.31 and 
427.32 
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Noseworthy, 
2016 
70.5 (62–78) 56 [4 (2–5)] 2 (1–3) Y 427.31 
Palamaner 
Subash 
Shantha, 2017 
75* NA 
(male 
vs 
female 
cohorts) 
2.3 [3.8] 1.7 Unclear 427.31 
Seeger, 2015 –  64 1.91 (1.09) [2.8 
(1.6)] 
1.18 
(1.13) 
Unclear –  
Tepper, 2015 –  63.2 –  –  Unclear –  
Villines, 2015 73.8 (9.3) 58.9 [3.9 (1.7)] 3.4 (1.3) Y –  
Yao, 2016 71 (61–81) 53 [3.2 (2–5)] 2 (1–3) Y 427.31 
Abbreviations: IQR, Interquartile Range; N, No; NA, Not Applicable; NR, Not Reported; Y, Yes. 
*Exact overall value not reported. Presented value is approximation based on multiple cohorts.  
 		 		 		 		 		 		
 
 
	 
 
26	
Major Bleeding Definitions 
The algorithm used to define whether a patient exhibited major bleeding is critical 
when using real-world data. Depending on the data source, real-world evidence often 
lacks clinical markers and values that point to major bleeding, so researchers are left to 
design their own criteria. The International Society of Thrombosis and Haemostasis 
(ISTH) classification of major bleeding includes the following: 1) bleeding that results in 
death; 2) symptomatic bleeding in a critical area or organ (intracranial, intraspinal, 
intraocular, retroperitoneal, intraarticular, pericardial, intramuscular with compartment 
syndrome); 3) a drop in hemoglobin of ≥ 2 g/l; 4) a transfusion of ≥ 2 units of red blood 
cells; or 5) bleeding that requires surgical intervention.43 Due to the complexity of the 
definition, real-world data sources often fail to capture the detail of laboratory data 
needed to replicate the definition in analyses and no studies reviewed for this analysis 
followed the criteria precisely. Thus, studies used varying definitions of major bleeding, 
although most studies included intracranial and extracranial bleeding occurrences as 
evidence of major bleeding. Two studies used a much more restrictive definition of major 
bleeding, defined as extracranial bleeding with anemia, hemothorax, hematuria, epistaxis, 
or bleeding in the eye.61,73 Table 5 describes the diversity of definitions for major 
bleeding across studies profiled for the present review. Although the definitions included 
in the table are not comprehensive of those used by all 26 studies, those listed are 
generally representative of the definitions most commonly used by a majority of studies.  
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Table 5. Major Bleeding Definitions. Real-world data are limited in that 
depending on the source, many definitive clinical markers are often not 
present. Researchers must often define specific algorithms for identifying 
outcomes of interest, such as major bleeding. This practice results in 
differences across studies that carry throughout the analyses and may limit the 
ability to draw direct comparisons in findings across studies.  
First Author, 
Year 
Definition 
Graham, 2015 Bleeding event with (i) a critical site code, (ii) a transfusion, or (iii) death 
Graham, 2016 
Major extracranial bleeding was defined as a fatal 
bleeding event, a hospitalized bleeding event requiring 
transfusion, or hospitalization with hemorrhage into an 
extracranial critical site (i.e. intra- spinal, intraarticular, 
intraocular, pericardial, retroperitoneal, or intramuscular 
with compartment syndrome) 
Laliberte, 2014 
Major bleeding defined as a combination of 
hemophthalmos, except current, retinal hemorrhage, 
choroidal hemorrhage, conjunctival hemorrhage, orbital 
hemorrhage, vitreous hemorrhage, hemopericardium, 
subarachnoid hemorrhage, intracerebral hemorrhage, 
other unspecified intracranial hemorrhage, 
hemoperitoneum (non-traumatic), hemarthrosis, 
subarachnoid, subdural, and extradural hemorrhage 
following injury, other unspecified 
Lip, 2016 Major bleeding was defined as bleeding requiring hospitalization. 
Noseworthy, 2016 Major bleeding included gastrointestinal bleeding, intracranial bleeding, and bleeding from other sites 
Seeger, 2015 Major intra- or extracranial bleeding 
Villines, 2015 Inclusive of hemorrhagic stroke, major intracranial bleeding, and major extracranial bleeding 
Source: Adapted from Deitelzweig, 2017 
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Overall Risk of Bleeding Comparisons 
 
Twenty-one studies compared the risk of major bleeding from various DOACs to 
warfarin and thirteen studies described the risk of DOACs compared to other DOACs. 
There were eight studies that provided comparisons of both DOACs vs warfarin and 
inter-DOAC profiles. However, there were no studies that compared edoxaban to 
warfarin or any available DOAC. Table 6 shows the HRs for each comparison. 
 
Table 6. Risk of Major Bleeding. Overall, the majority of studies found DOACs 
to have lower bleeding rates than warfarin while inter-DOAC comparisons were 
mixed. Apixaban demonstrated the most support compared to warfarin and other 
DOACs.  
  Study  Hazard Ratio 
DOACs vs Warfarin   
Apixaban vs Warfarin   
  Adeboyeje, 2016 HR, 0.52; 95% CI, 0.41 - 0.67 
  Amin, 2015 HR, 0.71; 95% CI, 0.61 - 0.83 
  Coleman, 2017 HR, 0.79; 95% CI, 0.38 - 1.64 
  Deitelzweig, 2017 HR, 0.53; 95% CI, 0.42 - 0.66 
  Deitelzweig, 2015 HR, 0.58; 95% CI, 0.44 - 0.75 
  Kamble, 2015 HR, 0.53; 95% CI, 0.29 - 0.97 
  Li, 2018 2.5 mg: HR, 0.63; 95% CI, 0.49 - 0.81 
  Li, 2018 5 mg: HR, 0.59; 95% CI, 0.53 - 0.66 
  Lin, 2015 HR, 0.75; 95% CI, 0.63 - 0.89 
  Lip, 2016 HR, 0.52; 95% CI, 0.30 - 0.89 
  Lip, 2016 * HR, 0.53; 95% CI, 0.39 - 0.71 
  Martinez, 2018 HR, 0.61; 95% CI, 0.39 - 0.93 
  
Palamaner Subash 
Shantha, 2017 HR, 0.91; 95% CI, 0.75 - 1.11 
  Yao, 2016 HR, 0.45; 95% CI, 0.34 - 0.59 
Dabigatran vs Warfarin   
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  Adeboyeje, 2016 HR, 0.67; 95% CI, 0.60 - 0.76 
  Bengtson, 2017 HR, 1.04; 95% CI, 0.88 - 1.22 
  Coleman, 2017 HR, 0.58; 95% CI, 0.26 - 1.27 
  Graham, 2015 HR, 0.97; 95% CI, 0.88 - 1.07 
  Hernandez, 2015 HR, 1.58; 95% CI, 1.36 - 1.83 
  Kamble, 2015 HR, 0.82; 95% CI, 0.58 - 1.16 
  Lauffenburger, 2015 HR, 1.11; 95% CI, 1.02 - 1.22 
  Lip, 2016 HR, 0.88; 95% CI, 0.64 - 1.21 
  Lip, 2016* HR, 0.69; 95% CI, 0.50 - 0.96 
  Martinez, 2018 HR, 0.92; 95% CI, 0.62 - 1.37 
  
Palamaner Subash 
Shantha, 2017 HR, 0.73; 95% CI, 0.59 - 0.90 
  Villines, 2015 HR, 0.87; 95% CI, 0.74 - 1.03 
Rivaroxaban vs Warfarin   
  Adeboyeje, 2016 HR, 1.00; 95% CI, 0.89 - 1.12 
  Coleman, 2017 HR, 1.07; 95% CI, 0.71 - 1.61 
  Coleman, 2016 HR, 0.53; 95% CI, 0.35 - 0.79 
  Kamble, 2015 HR, 1.08; 95% CI, 0.85 - 1.39 
  Laliberte, 2014 HR, 1.08; 95% CI, 0.71 - 1.64 
  Lip, 2016 HR, 1.13; 95% CI, 0.91 - 1.41 
  Lip, 2016* HR, 0.98; 95% CI, 0.83 - 1.17 
  Martinez, 2018 HR, 1.06; 95% CI, 0.81 - 1.39 
  Norby, 2017 HR, 1.07; 95% CI, 0.95 - 1.20 
DOACs vs DOACs   
Apixaban vs Dabigatran   
  Abraham, 2017 HR, 0.39; 95% CI, 0.27 - 0.58 
  Adeboyeje, 2016 HR, 0.78; 95% CI, 0.59 - 1.01 
  Amin, 2015 HR, 0.87; 95% CI, 0.72 - 1.05 
  Deitelzweig, 2017 HR, 0.68; 95% CI, 0.44 - 1.04 
  Lin, 2015 HR, 0.91; 95% CI, 0.73 - 1.13 
  Lip, 2016 * HR, 0.71; 95% CI, 0.47 - 1.07 
  Noseworthy, 2016 HR, 0.50; 95% CI, 0.36 - 0.70 
  Tepper, 2015 HR, 1.01; 95% CI, 0.91 - 1.12 
Apixaban vs Rivaroxaban   
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  Abraham, 2017 HR, 0.33; 95% CI, 0.22 - 0.49 
  Adeboyeje, 2016 HR, 0.52; 95% CI, 0.40 - 0.68 
  Amin, 2015 HR, 0.69; 95% CI, 0.59 - 0.81 
  Deitelzweig, 2017 HR, 0.43; 95% CI, 0.33 - 0.54 
  Deitelzweig, 2015 HR, 0.65; 95% CI, 0.50 - 0.85 
  Lin, 2015 HR, 0.68; 95% CI, 0.57 - 0.81 
  Lip, 2016 * HR, 0.55; 95% CI, 0.41 - 0.74 
  Noseworthy, 2016 HR, 0.39; 95% CI, 0.28 - 0.54 
  Tepper, 2015 HR, 0.74; 95% CI, 0.66 - 0.81 
Dabigatran vs Rivaroxaban   
  Adeboyeje, 2016 HR, 0.67; 95% CI, 0.58 - 0.78 
  Graham, 2016 HR, 0.68; 95% CI, 0.60 - 0.78 
  Lip, 2016 * HR, 0.95; 95% CI, 0.67 - 1.35 
  Noseworthy, 2016 HR, 0.77; 95% CI, 0.65 - 0.91 
  Seeger, 2015 HR, 0.75; 95% CI, 0.65 - 0.87 
Rivaroxaban vs Dabigatran   
  Abraham, 2017 HR, 1.20; 95% CI, 1.00 - 1.45 
  Norby, 2017 HR, 1.28; 95% CI, 1.06 - 1.54 
  
Palamaner Subash 
Shantha, 2017 HR, 1.24; 95% CI, 0.99 - 1.55 
  
Apixaban compared to Warfarin 
 
Thirteen studies compared the risk of major bleeding between apixaban and 
warfarin. The majority of studies (n = 11) reported apixaban to be associated with a 
significantly lower risk of major bleeding compared to warfarin. The range of HRs was 
0.52 to 0.75 and the 95% confidence intervals ranged from 0.29 to 0.97 among models 
that were statistically significant.  One study included dose-dependent comparisons (2.5 
mg and 5.0 mg), and found that both exhibited statistically significant reductions 
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compared to warfarin.58 Of note, two studies reported insignificant reductions of major 
bleeding for apixaban compared to warfarin.65,74   
Of the 13 studies that compared apixaban with warfarin, four studies were 
independently conducted and the remaining were sponsored by industry. Three of the 
four non-industry studies found apixaban to be significantly associated with a reduced 
risk of bleeding compared to warfarin, while Palamaner Subash Shantha and colleagues 
reported a numerical yet insignificant reduction.  
 
Dabigatran compared to Warfarin	
 
There were 12 studies that compared dabigatran with warfarin. Only three studies 
reported statistically significant reductions of major bleeding with dabigatran, although a 
total of six other studies reported numerically lower risk without significance. The HRs 
ranged from 0.58 to 1.58 among all studies. Upon initial analysis between studies, it is 
not immediately clear what accounts for the extreme variation of findings for dabigatran. 
The study design and patient populations of those studies comparing dabigatran and 
warfarin were generally similar (as previously shown in Table 4). The differences of data 
sources used across studies may explain some of the variation, although further analysis 
is needed to confirm this hypothesis.  
Among the 12 studies that assessed the risk of bleeding from dabigatran compared 
to warfarin, seven were independently conducted and five were sponsored from industry. 
Of the non-industry studies, two found statistically significant reductions in bleeding risk 
with use of dabigatran compared to warfarin. Additional analysis should be pursued to 
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investigate the reasons why to date, real-world evidence only partially supports the 
findings of clinical trial data for dabigatran.  
 
Rivaroxaban compared to Warfarin	
 
Nine studies compared rivaroxaban to warfarin, and only one study by Coleman 
and colleagues reported a significant reduction of major bleeding with use of rivaroxaban 
(HR, 0.53; 95% CI, 0.35 - 0.79). A range of HRs from 0.53 to 1.13 was observed 
between all studies. The analyses reviewed provide little evidence for significant 
reductions in bleeding when using rivaroxaban.  
Of the nine studies which examined rivaroxaban compared to warfarin, seven 
publications were sponsored by industry and two were conducted independently. 
Independent studies reported no significant reductions in bleeding when using warfarin. 
Clinical trial data for rivaroxaban suggested slight reductions in intracranial bleeding and 
fatal bleeding, however, as shown the real-world data does not yet complement these 
findings.   
 
Apixaban compared to Dabigatran 
 
A total of 8 studies compared apixaban to dabigatran in terms of major bleeding 
risk. Only two studies reported a significant reduction with use of apixaban, while 5 
others reported numerical reductions, but statistically insignificant results supporting 
apixaban. One study reported a lower risk of bleeding with use of dabigatran, but lacked 
statistical significance as well (HR, 1.01; 95% CI, 0.91 - 1.12).67 Additional comparisons 
of apixaban and dabigatran are further warranted in the real-world setting.  
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Three studies of the eight identified were independently conducted while the 
remaining five were industry sponsored. Among the independent studies, two studies 
reported statistically significant results favoring apixaban and another reported numerical 
but slightly insignificant results supporting apixaban. Among the industry-sponsored 
studies, all five were sponsored at least in part by Pfizer or Bristol-Myers Squibb, the 
makers of apixaban. However, none of those studies reported significant reductions with 
use of apixaban compared to dabigatran. In fact, one study by Tepper et al found a 
slightly higher risk of using apixaban in place of dabigatran (HR, 1.01; 95% CI, 0.91 - 
1.12). 
 
Apixaban compared to Rivaroxaban	
 
Nine studies compared apixaban to rivaroxaban. All studies reporting HRs were 
statistically significant, which strongly supports the notion that apixaban results in lower 
bleeding events compared to rivaroxaban. HRs ranged from 0.33 to 0.74 (95% CI range 
0.22 to 0.85).  
Among the nine studies evaluating apixaban and rivaroxaban against one another, 
three studies were independently conducted and six were sponsored by industry. Due to 
the robust evidence in support of apixaban over rivaroxaban across studies, it appears that 
sponsorship by industry did not greatly affect or bias the overall outcome.  
 
Dabigatran compared to Rivaroxaban 
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Five studies compared dabigatran to rivaroxaban, of which four studies reported a 
significant reduction of bleeding risk with use of dabigatran. The HRs ranged from 0.67 
to 0.77 (95% CI range 0.58 to 0.91) among those models with significant results.  
Among the five studies, three were independently conducted and two were 
published by industry-sponsored projects. The independent studies unanimously reported 
significant reductions in bleeding risk observed after dabigatran use when compared to 
rivaroxaban. 
 
Rivaroxaban compared to Dabigatran 
 
 
 There were three studies that compared rivaroxaban to dabigatran, two of which 
reported significant increases in the risk of bleeding with use of rivaroxaban. The HRs 
ranged from 1.20 to 1.28 (95% CI range 0.99 to 1.55) among all three studies. Similarly, 
all three studies were independently conducted without funds from the pharmaceutical 
industry.  
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DISCUSSION 
  
The present analysis provides a comprehensive literature review of real-world 
database studies that compare the risk of major bleeding associated with all FDA-
approved DOACs with warfarin or other DOACs. Overall, studies showed similar or 
lower risk of major bleeding with the use of DOACs instead of warfarin in patients with 
AF. Specifically, apixaban was the DOAC most consistently shown to result in 
significantly lower bleeding risk. Dabigatran was shown to be relatively similar to 
warfarin, although numerically (without statistical significance) it had a comparable 
number of studies to apixaban which reported lower bleeding risk when compared to 
warfarin. Results for rivaroxaban were somewhat mixed; rivaroxaban was numerically 
associated with an equal or slightly higher risk of bleeding compared to warfarin in many 
studies. Finally, edoxaban was not assessed by any identified publications, which 
represents a major area of research which should be pursued in the future when more 
real-world data become more available.  
The results of this review generally support prior research into the subject, both 
from clinical trials and other previous reviews of real-world evidence. For example, the 
ARISTOTLES trial22 demonstrated that apixaban resulted in a 31% reduction of major 
bleeding compared to warfarin and similar reductions of risk were shown in the 11 
studies that were fully reviewed for this analysis which analyzed apixaban compared to 
warfarin. Neither the ROCKET-AF trial25 (rivaroxaban vs warfarin) nor the RE-LY trial23 
(dabigatran vs warfarin) for the higher dose of the dabigatran showed as high of 
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reductions in bleeding risk compared to warfarin as the trial for apixaban. However, the 
low dose of dabigatran showed a significant 20% reduction of bleeding compared to 
warfarin in the RE-LY trial, which is also relatively consistent with the findings of this 
review.  
The present review did not find significant differences between bleeding risk 
estimates in the United States versus other countries when compared to similar reviews or 
meta-analyses that assessed international studies using data from Asia or Europe.43,75–77 
For example, in a 2017 study sponsored by Pfizer, the manufacturer of apixaban, 
Deitelzweig and colleagues reviewed publications and abstracts that investigated the 
bleeding risk of DOACs and vitamin K antagonists (i.e. warfarin) among available U.S. 
and international studies.43 They made similar conclusions, including that real-world 
evidence confirmed that DOACs were associated to similar or lower risks of bleeding 
compared to warfarin. They also noted the increased frequency and statistical 
significance of studies reporting apixaban to be associated with lower bleeding compared 
to models assessing dabigatran and rivaroxaban’s bleeding risk. The current analysis, 
however, included updated literature not otherwise included in the previous Deitelzweig 
review. A total of 12 additional studies from the U.S. were 
included.44,47,49,50,54,57,58,60,62,63,65,74 It is initially unclear why the studies published prior to 
the Deitelzweig review were not included in their review. It stands only to reason that the 
authors of the previous study considered the populations of those studies to be ineligible 
to their given criteria. Regardless, the majority of these studies provide additional support 
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for the conclusions listed above in consideration of the reduced risk of bleeding with use 
of apixaban.  
Furthermore, the additional studies in this review do not suggest any significant 
bias in prior reviews due to funding from Pfizer or any other invested industry 
companies. Many studies were funded by the manufacturers of a DOAC agent and those 
studies often found favorable results to the pharmaceutical company’s respective drug.  
Of the 26 studies investigated for the present analysis, 14 were funded by pharmaceutical 
manufacturers (industry) and 12 were completed from independent or non-industry 
researchers. Among industry-funded articles, nine were backed by Pfizer or Bristol-
Myers Squibb (apixaban), three were funded by Bayer AG or Janssen Pharmaceuticals 
(rivaroxaban), and two were funded by Boehringer Ingelheim (dabigatran).  
Among the nine studies funded by Pfizer or Bristol-Myers Squibb, all reported 
apixaban to be either superior or statistically equivalent to all other DOACs or warfarin 
using administrative claims data. The two manufacturers have demonstrated significant 
financial investment into providing evidence of the superiority of apixaban as DOAC of 
choice for AF therapy. Interestingly, however, Pfizer has not pursued publication of the 
topic using an EMR data source. It stands to reason that if Pfizer is able to produce more 
evidence in the future demonstrating apixaban’s superiority in populations measured by 
EMR or other data sources, then providers will be more willing to prescribe apixaban to 
patients over the competitor products, dabigatran or rivaroxaban. On the other hand, it is 
reasonable to presume that additional investments made by Boehringer Ingelheim, Bayer 
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AG or Janssen Pharmaceuticals may conflict with the findings of Pfizer’s research and 
push prescribers to reconsider the lead DOAC.  
In consideration of the findings regarding rivaroxaban, clinical trial data from 
Patel et al suggested that significant reductions in intracranial hemorrhage (0.5% vs. 
0.7%, P = 0.02) and fatal bleeding (0.2% vs. 0.5%, P = 0.003) were observed after use of 
rivaroxaban. The trial noted similar overall (major and nonmajor) bleeding in both 
rivaroxaban and warfarin groups. Real-world evidence collected from this review 
generally did not support any significant findings in reductions of bleeding risk except in 
one study by Coleman et al conducted in 2016. Moreover, when compared against 
apixaban or dabigatran, numerous studies provided strong evidence of rivaroxaban’s 
inferiority against the other two DOACs. Recently, the findings of the original clinical 
trial have been called into question after a blood-testing device used in the trial was 
shown to be faulty. Nearly 20,000 lawsuits against rivaroxaban have been filed against 
the manufacturers Janssen and Bayer AG, many of which claim patients were 
insufficiently warned against the risks of bleeding from rivaroxaban.78  
Virtually all of the data sources used in this review utilized administrative claims 
data. A future area of research should focus on the production of similar studies that 
assess bleeding rates using EMR data sources. Only one abstract was identified which 
utilized an EMR data source; it reported that apixaban was superior in the reduction of 
major bleeding and was funded by Pfizer.79 By analyzing additional EMR sources, 
confirmation of similar trends could be realized in a clinically relevant data source.  
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A notable limitation of this review is the lack of stratification of different types of 
major bleeding. Others have reported that the subtypes of major bleeding (i.e., cranial vs 
gastrointestinal or other areas of bleeding) may differ between agents.75 An additional 
limitation is that the articles reviewed were not assessed for quality. Tools that could be 
used in future assessments to filter studies by quality include the Cochrane 
Collaboration’s risk of bias assessment or the Agency for Healthcare Research and 
Quality (AHRQ) Risk of Bias Assessment tool, both of which are used to measure the 
potential bias in study design, analysis and reporting of observational studies.80 Finally, 
when considering the results of the present literature review, it should be carefully noted 
that although populations were generally similar in terms of sex and age, the initial 
bleeding risk across populations differed dramatically. Among those studies that reported 
HAS-BLED scores (the standard for estimating initial bleeding risk of a patient), a range 
of 1.2 – 3.4 was observed, indicating that across all studies, patients ranged from low risk 
to very high risk in the baseline period before the anticoagulant treatment was given. 
Without additional analysis to standardize all populations (via meta-analysis), one is 
unable to confidently predict the entirety of the implications from this finding in the 
overall population.  
The results of this review also do not necessarily imply that apixaban should 
always be used in place of other agents. This review does not consider effectiveness 
(reduction in stroke, pulmonary embolism or VTE events) or other personal factors that 
should be considered when prescribing oral anticoagulant therapy to patients. Similarly, 
the recent development and subsequent FDA approval of reversal agents for rivaroxaban 
	 
 
40	
and apixaban earlier this year provides physicians with a new and groundbreaking tool 
for treating immediate life threatening bleeds. Therefore, this advance in therapy may 
mitigate some of the perceived risk of prescribing either drug.  
The present analysis reviewed real-world evidence studies that compared the risk 
of major bleeding between available DOACs and warfarin or against other DOACs in 
patients with AF. In conclusion, DOACs exhibited equal or lower risk of major bleeding 
compared to warfarin. Additionally, not all DOACs showed the same risk. Apixaban 
most consistently demonstrated the lowest risk of bleeding among all available DOACs. 
Dabigatran also decreases the risk of bleeding, but with less evidence than apixaban. 
Rivaroxaban resulted in similar bleeding risk compared to warfarin and edoxaban has not 
yet been studied in real-world settings. In combination with the findings from RCTs, 
clinicians should consider the real-world implications of prescribing oral anticoagulants 
to patients with AF. 
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